There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

As of January 2025, Ozempic's weekly prescriptions were reported at 576,790, while Mounjaro (tirzepatide ... shortages were limited to the lowest dose for Wegovy. Novo Nordisk has been actively ...

Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management. Klarity connects you with healthcare ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes. Adults without diabetes lost 15% to 20.9% of their body weight, depending on the dosage.

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure ...